The evaluation of the antiviral activity performed to support the development of an “investigational” product should include an assay directed against a broad range of clinical and laboratory viral isolates, including different clades, subtypes, or genotypes. To this regard, we found that the envelope surface glycoprotein E1 (A226V) adaptive mutation, which improved the fitness of CHIKV for a secondary vector, Aedes albopictus (facilitating its spread during the outbreaks in the Indian Ocean area, in India and in north-eastern Italy), can significantly affect the sensitivity of CHIKV to the antiviral action of different type I IFN preparations. In particular, CHIKV strain (East Central South African [ECSA]) with the A226V mutation was more sensitive to IFNs in the Vero cell line compared to the viral strain without A226V. Second, the assessment of antiviral activity to support the development of an “investigational” product requires to test at least the effect of an increasing multiplicity of infection (MOI) and, whenever possible, the antiviral activity in different cellular lines, giving priority to human cells (which are more likely to reflect in vivo condition). In this context, we found that the antiviral activity of IFNs against CHIKV strains significantly decreased by increasing the MOI. Furthermore, the authors estimated the antiviral activity of IFNα2a against CHIKV in Vero cells only. In relation to that, we found that the antiviral activity of IFNα, IFNβ, and IFNω against both strains of CHIKV is different in Hep-2, a human cell line, compared to that recorded in Vero cells.

Antiviral Activity of the Combination of Interferon and Ribavirin Against Chikungunya Virus: Are the Results Conclusive? / Scagnolari, Carolina; Caputo, Beniamino; Rezza, Giovanni; Antonelli, Guido. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - STAMPA. - 215:3(2017), pp. 492-493. [10.1093/infdis/jiw579]

Antiviral Activity of the Combination of Interferon and Ribavirin Against Chikungunya Virus: Are the Results Conclusive?

SCAGNOLARI, CAROLINA;CAPUTO, BENIAMINO;ANTONELLI, Guido
2017

Abstract

The evaluation of the antiviral activity performed to support the development of an “investigational” product should include an assay directed against a broad range of clinical and laboratory viral isolates, including different clades, subtypes, or genotypes. To this regard, we found that the envelope surface glycoprotein E1 (A226V) adaptive mutation, which improved the fitness of CHIKV for a secondary vector, Aedes albopictus (facilitating its spread during the outbreaks in the Indian Ocean area, in India and in north-eastern Italy), can significantly affect the sensitivity of CHIKV to the antiviral action of different type I IFN preparations. In particular, CHIKV strain (East Central South African [ECSA]) with the A226V mutation was more sensitive to IFNs in the Vero cell line compared to the viral strain without A226V. Second, the assessment of antiviral activity to support the development of an “investigational” product requires to test at least the effect of an increasing multiplicity of infection (MOI) and, whenever possible, the antiviral activity in different cellular lines, giving priority to human cells (which are more likely to reflect in vivo condition). In this context, we found that the antiviral activity of IFNs against CHIKV strains significantly decreased by increasing the MOI. Furthermore, the authors estimated the antiviral activity of IFNα2a against CHIKV in Vero cells only. In relation to that, we found that the antiviral activity of IFNα, IFNβ, and IFNω against both strains of CHIKV is different in Hep-2, a human cell line, compared to that recorded in Vero cells.
2017
Interferon, Ribavirin,t Chikungunya Virus, emerging viral infections
01 Pubblicazione su rivista::01b Commento, Erratum, Replica e simili
Antiviral Activity of the Combination of Interferon and Ribavirin Against Chikungunya Virus: Are the Results Conclusive? / Scagnolari, Carolina; Caputo, Beniamino; Rezza, Giovanni; Antonelli, Guido. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - STAMPA. - 215:3(2017), pp. 492-493. [10.1093/infdis/jiw579]
File allegati a questo prodotto
File Dimensione Formato  
Scagnolari_Antiviral_2017.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 85.83 kB
Formato Adobe PDF
85.83 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/949488
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact